Stock NBSE NEUBASE THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages NeuBase Therapeutics, Inc.

Equities

NBSE

US64132K2015

Market Closed - Nasdaq
Other stock markets
 21:30:00 10/05/2024 BST 		5-day change 1st Jan Change
0.378 USD -3.20% Intraday chart for NeuBase Therapeutics, Inc. -6.67% -48.93%
03-26 Wall Street Set to Open Modestly Higher Tuesday Ahead Consumer Confidence Reading MT
03-26 US Futures Trend Higher Ahead of Durable Goods, House Prices, Consumer Confidence Readings MT

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Wall Street Set to Open Modestly Higher Tuesday Ahead Consumer Confidence Reading
US Futures Trend Higher Ahead of Durable Goods, House Prices, Consumer Confidence Readings
Top Premarket Decliners
NeuBase Therapeutics, Inc. Announces CEO Changes
NeuBase Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Neubase Therapeutics, Inc. Announces Franklyn G. Prendergast Board of Directors Passed Away
Top Premarket Decliners
Top Midday Gainers
NEUBASE THERAPEUTICS SHARES UP 40% AFTER SYMETRYX CORPORATION AC…
Top Premarket Gainers
NeuBase Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
NeuBase Therapeutics to Explore Strategic Alternatives
NeuBase Therapeutics, Inc. Presents Non-Human Primate Data Illustrating Stealth Editors Are Non-Immunogenic, Opening the Door to Redosing
NeuBase Therapeutics Launches $5 Million Registered Direct Offering, Concurrent Private Placement
Neubase Therapeutics, Inc. Announces Positive Preclinical Data Supporting the Capabilities of Stealth Editors
NeuBase Therapeutics, Inc. Announces Resignation of Eric J. Ende as Board of Director
NeuBase Therapeutics, Inc. Announces Formation of Gene Editing Advisory Board
NeuBase Therapeutics, Inc. Reports Earnings Results for the Second Quarter Ended March 31, 2023
NeuBase Therapeutics, Inc. Approves Change of Fiscal Year from the Twelve Months Beginning October 1 and Ending September 30 to the Twelve Months Beginning January 1 and Ending December 31
NeuBase Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2022
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. NBSE Stock
  4. News NeuBase Therapeutics, Inc.
  5. Other languages